Chronic lymphocytic leukemia (CLL) is a type of leukemia and the most common form of cancer affecting adults. It is a slow-growing cancer affecting the blood and bone marrow and involves white blood cells called lymphocytes. Some people may live for many years with symptoms, while others may need treatment for their disease.
Recent advances have changed how some patients with this disease are managed and treated. More targeted therapies have been developed that target specific pathways. For some individuals, additional therapies can be used to target the disease while specific measures are in place to decrease your risk of infection. Additionally, management of CLL is no longer simply a matter of waiting for symptoms to appear. Techniques to predict how long a person may live with the disease have been established. A broad range of advanced therapies are now available to help individuals manage their condition with optimal quality of life. These treatment options are constantly evolving as new research emerges.
Understanding Chronic Lymphocytic Leukemia
Unlike other cancers which are typically identified based on their symptoms, Chronic Lymphocytic Leukemia or CLL is often diagnosed incidentally. Most individuals discover they have the disease during a routine blood test and have not shown any symptoms at the time. Gradually, however, the disease may get worse, robbing victims of their physical well-being, deplete their financial resources, and disrupt their personal, spiritual, and professional worlds.
Some common symptoms associated with CLL may include:
- Fatigue
- Swollen lymph nodes
- Frequent infections
- Night sweats
- Unexplained weight loss
- Easy bruising or bleeding
After diagnosis, most patients do not require treatment right away. Some patients may be entered into an active monitoring pathway, called watchful waiting, until signs and symptoms of a disease develop.
When Treatment Becomes Necessary
Decisions about starting treatment, in addition to being individualized based on symptoms, blood counts, overall health and disease progression, often require careful consideration of potential benefits and risks.
Doctors may recommend treatment if a patient experiences:
- Significant fatigue affecting daily life
- Enlarged lymph nodes or spleen
- Rapidly increasing lymphocyte counts
- Recurrent infections
- Low red blood cell or platelet levels
The treatment of bladder cancer is not always intended to be curative. The focus is on control of the disease, relief of symptoms, and continuation of good quality of life. Treatment of bladder cancer also helps to delay the progression of the disease.
Traditional Approaches to CLL Treatment
For many years, chemotherapy-based approaches have been the main-stay of treatment for patients with CLL. This class of drugs are designed to kill rapidly dividing cancer cells that are found throughout the body. Chemotherapy is often paired with other types of therapies, and one of the most common is chemoimmunotherapy, or chemotherapy given with certain immunotherapy drugs. These medications boost the body’s own immune system to recognize and attack tumor cells more effectively.
Traditional treatment approaches may include:
- Chemotherapy combinations
- Monoclonal antibody therapies
- Immunotherapy-based regimens
- Stem cell transplantation in select cases
Even after they were taken off the market, these medications continued to be used for some patients with CML but more targeted options for treating this disease have since come to the forefront.
The Rise of Targeted Therapies
There has been significant progress in the development of effective and safe chronic lymphocytic leukemia treatments. In addition to advances with traditional chemotherapy options, targeted therapies have emerged as novel treatments that specifically target proteins or pathways critical for leukemia cell survival. These CLL targeted treatments target to disrupt cancer cell function. They are designed to have minimal harm to normal body cells.
Common targeted therapy approaches include:
- BTK inhibitors
- BCL-2 inhibitors
- PI3K inhibitors
BTK (BRCR-ABL-TYK2 like) inhibitors have emerged as major therapeutic options for the treatment of patients with chronic lymphocytic leukemia (CLL) as these agents target biological pathways crucial for the expansion and survival of malignant B cells and have the potential to transform management of this disease. Targeted therapies are often taken in pill form and offer patients an alternative and often more convenient form of treatment when compared to other forms of therapy.
Understanding BTK Inhibitors in CLL
Bruton’s tyrosine kinase (BTK) is essential for the development and survival of malignant B cells in CLL. BTK inhibitors aim to intervene in this pathway leading to a slowing or stopping of the disease progression. In addition to the chemokine receptor antagonists, several BTK inhibitors have entered clinical trials and are now approved for the treatment of CLL in both newly diagnosed and relapsed / refractory patients.
Abstract goal(s) of therapy – Potential benefits associated with BTK inhibitor therapy:
- Long-term disease control
- Improved progression-free survival
- Oral treatment convenience
- Reduced reliance on traditional chemotherapy
In addition to the generations of BTK inhibitors already in research and development clinical, newer generations are being developed with improved selectivity to mitigate side effects and other toxicities.
Emerging Therapies and Ongoing Research
Research into chronic lymphocytic leukemia treatments is advancing rapidly. Scientists and clinicians are seeking to improve the effectiveness of current treatments, to decrease toxicity and to prevent resistance.
Some emerging areas of research include:
- Next-generation targeted therapies
- Combination treatment strategies
- CAR T-cell therapy
- Personalized medicine approaches
- Novel immunotherapies
Having multiple ingredients in a cancer treatment is becoming more common, according to experts. Each drug may treat cancer in a different way. And with tomorrow’s treatments, your doctor may soon be able to tell which combination, and even which is most effective for you based on your genetic make-up and your disease.
In addition to the standard treatments for leukemia, there are many clinical trials, which are an important means of advancing the field and may also offer treatment in trials to patients currently eligible for participation.
Managing Side Effects During Treatment
Though advances have been made to decrease some of the “bad” aspects of chemotherapy, in most cases, there can be some degree of adverse reactions when utilizing this form of cancer therapy. Side effects from chemotherapy, as with any other medicinal treatment, typically depend on the drug(s), dosage(s), and the overall health of the patient.
- feeling tired or having less energy, fever, infection (including respiratory tract infections, such as pneumonia, which can be serious), nausea, vomiting, diarrhea, stomach pain, and loss of appetite.
- Fatigue
- Increased infection risk
- Bruising or bleeding
- Nausea
- Diarrhea
- Joint or muscle discomfort
Side effects should be managed for long-term care of patients. Patients and their families should recognize any side effects that may become problematic and communicate these findings to their healthcare provider.
Supportive care strategies may include:
- Proper nutrition and hydration
- Regular monitoring and blood tests
- Physical activity within safe limits
- Stress management techniques
- Preventive infection measures
The Importance of Personalized Treatment Plans
Since every patient with CLL is unique, the management of individual cases requires consideration of a host of variables, including age, overall health, genetic features, and prior therapy. Additional factors, such as lifestyle considerations, also must be weighed.
Every patient is different, so is the treatment plan must reflect that. That’s why approach is always individualized. Your plan will likely incorporate a variety of treatments depending on your specific case.
- Disease stage and progression
- Genetic mutations
- Patient age and health status
- Previous treatment response
- Long-term treatment goals
This approach allows healthcare providers to select therapy options that match an individual patient’s situation best.
Looking Ahead in CLL Care
Ongoing research continues to evaluate new treatment approaches for CLL. Advances in targeted therapies, immunotherapies, and more personalized approaches to treating and managing individual forms of leukemia continue to occur.
While there are still many battles to fight with this aggressive and insidious disease, in some cases, CLL is managed with ongoing monitoring and treatment. Researchers continue to work hard at developing new therapies that are more effective, better tolerated, and lead to longer durations of response. There’s a steady flow of important developments concerning chronic lymphocytic leukemia, and as the disease is better understood, advanced treatments are expected to emerge that will be personalized, targeted, and more than focused on patient survival quality of life, worldwide.
